Literature DB >> 23344514

Magnetic resonance-guided shielding of prefocal acoustic obstacles in focused ultrasound therapy: application to intercostal ablation in liver.

Rares Salomir1, Lorena Petrusca, Vincent Auboiroux, Arnaud Muller, Maria-Isabel Vargas, Denis R Morel, Thomas Goget, Romain Breguet, Sylvain Terraz, Jerry Hopple, Xavier Montet, Christoph D Becker, Magalie Viallon.   

Abstract

OBJECTIVES: The treatment of liver cancer is a major public health issue because the liver is a frequent site for both primary and secondary tumors. Rib heating represents a major obstacle for the application of extracorporeal focused ultrasound to liver ablation. Magnetic resonance (MR)-guided external shielding of acoustic obstacles (eg, the ribs) was investigated here to avoid unwanted prefocal energy deposition in the pathway of the focused ultrasound beam.
MATERIALS AND METHODS: Ex vivo and in vivo (7 female sheep) experiments were performed in this study. Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) was performed using a randomized 256-element phased-array transducer (f∼1 MHz) and a 3-T whole-body clinical MR scanner. A physical mask was inserted in the prefocal beam pathway, external to the body, to block the energy normally targeted on the ribs. The effectiveness of the reflecting material was investigated by characterizing the efficacy of high-intensity focused ultrasound beam reflection and scattering on its surface using Schlieren interferometry. Before high-intensity focused ultrasound sonication, the alignment of the protectors with the conical projections of the ribs was required and achieved in multiple steps using the embedded graphical tools of the MR scanner. Multiplanar near real-time MR thermometry (proton resonance frequency shift method) enabled the simultaneous visualization of the local temperature increase at the focal point and around the exposed ribs. The beam defocusing due to the shielding was evaluated from the MR acoustic radiation force impulse imaging data.
RESULTS: Both MR thermometry (performed with hard absorber positioned behind a full-aperture blocking shield) and Schlieren interferometry indicated a very good energy barrier of the shielding material. The specific temperature contrast between rib surface (spatial average) and focus, calculated at the end point of the MRgHIFU sonication, with protectors vs no protectors, indicated an important reduction of the temperature elevation at the ribs' surface, typically by 3.3 ± 0.4 in vivo. This was translated into an exponential reduction in thermal dose by several orders of magnitude. The external shielding covering the full conical shadow of the ribs was more effective when the protectors could be placed close to the ribs' surface and had a tendency to lose its efficiency when placed further from the ribs. Hepatic parenchyma was safely ablated in vivo using this rib-sparing strategy and single-focus independent sonications.
CONCLUSIONS: A readily available, MR-compatible, effective, and cost-competitive method for rib protection in transcostal MRgHIFU was validated in this study, using specific reflective strips. The current approach permitted safe intercostal ablation of small volumes (0.7 mL) of liver parenchyma.

Entities:  

Mesh:

Year:  2013        PMID: 23344514     DOI: 10.1097/RLI.0b013e31827a90d7

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  7 in total

1.  A Novel Concept of a Phased-Array HIFU Transducer Optimized for MR-Guided Hepatic Ablation: Embodiment and First In-Vivo Studies.

Authors:  Orane Lorton; Pauline C Guillemin; Yacine M'Rad; Andrea Peloso; Sana Boudabbous; Caecilia Charbonnier; Ryan Holman; Lindsey A Crowe; Laura Gui; Pierre-Alexandre Poletti; Alexis Ricoeur; Sylvain Terraz; Rares Salomir
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

2.  Respiratory-gated MRgHIFU in upper abdomen using an MR-compatible in-bore digital camera.

Authors:  Vincent Auboiroux; Lorena Petrusca; Magalie Viallon; Arnaud Muller; Sylvain Terraz; Romain Breguet; Xavier Montet; Christoph D Becker; Rares Salomir
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

Review 3.  The road to clinical use of high-intensity focused ultrasound for liver cancer: technical and clinical consensus.

Authors:  Jean-Francois Aubry; Kim Butts Pauly; Chrit Moonen; Gail Ter Haar; Mario Ries; Rares Salomir; Sham Sokka; Kevin Michael Sekins; Yerucham Shapira; Fangwei Ye; Heather Huff-Simonin; Matt Eames; Arik Hananel; Neal Kassell; Alessandro Napoli; Joo Ha Hwang; Feng Wu; Lian Zhang; Andreas Melzer; Young-Sun Kim; Wladyslaw M Gedroyc
Journal:  J Ther Ultrasound       Date:  2013-08-01

4.  Spatiotemporal control of gene expression in bone-marrow derived cells of the tumor microenvironment induced by MRI guided focused ultrasound.

Authors:  Pierre-Yves Fortin; Matthieu Lepetit-Coiffé; Coralie Genevois; Christelle Debeissat; Bruno Quesson; Chrit T W Moonen; Jan Pieter Konsman; Franck Couillaud
Journal:  Oncotarget       Date:  2015-09-15

5.  Flooded Lung Generates a Suitable Acoustic Pathway for Transthoracic Application of High Intensity Focused Ultrasound in Liver.

Authors:  Thomas Günther Lesser; Carsten Boltze; Harald Schubert; Frank Wolfram
Journal:  Int J Med Sci       Date:  2016-09-19       Impact factor: 3.738

6.  Cytoreductive Surgical Treatment of Pleural Mesothelioma in a Porcine Model Using Magnetic-Resonance-Guided Focused Ultrasound Surgery (MRgFUS) and Radiofrequency Ablation (RFA).

Authors:  Marcia Costa; Carolina Fernandes; Matt Eames; Arik Hananel; John P Mugler; Jhosep Huaromo; Jack B Yang; Jaime Mata
Journal:  Tomography       Date:  2022-09-03

7.  An experimental model to investigate the targeting accuracy of MR-guided focused ultrasound ablation in liver.

Authors:  Lorena Petrusca; Magalie Viallon; Romain Breguet; Sylvain Terraz; Gibran Manasseh; Vincent Auboiroux; Thomas Goget; Loredana Baboi; Patrick Gross; K Michael Sekins; Christoph D Becker; Rares Salomir
Journal:  J Transl Med       Date:  2014-01-16       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.